期刊
RHEUMATOLOGY AND THERAPY
卷 7, 期 4, 页码 1045-1052出版社
SPRINGER
DOI: 10.1007/s40744-020-00246-z
关键词
Checkpoint inhibitors; Eosinophilic fasciitis; Immune-related adverse event; PD-1 inhibitor; Pembrolizumab
类别
Immune checkpoint inhibitors are a promising new therapeutic strategy in oncology that aims to eliminate cancer cells by enhancing patients' immune response against tumor antigens. Despite their beneficial effects, immune checkpoint inhibitors are also responsible for a plethora of autoimmune manifestations, known as immune-related adverse events. We present a case of eosinophilic fasciitis-like disorder in an 81-year-old patient treated with the programmed death cell protein 1 inhibitor pembrolizumab for non-small-cell lung cancer. The patient developed characteristic indurated skin lesions in his limbs after 11/2 years of treatment with pembrolizumab and a typical groove sign. Raynaud's syndrome was absent. A full-thickness biopsy confirmed the clinical diagnosis of an EF-like condition. Neither peripheral eosinophilia nor eosinophilic infiltrates in the skin biopsy were found. His symptoms improved after a 2.5-month CPI discontinuation and treatment with 16 mg of methylprednisolone slowly tapered to a dose of 4 mg. Eosinophilic fasciitis is a rare immune-related adverse event of CPI treatment; our literature search identified only 12 cases that fulfill the criteria of EF in patients receiving CPIs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据